Rod-cone dystrophies (RP) are a clinically and genetically heterogeneous group of inherited retinal disorders characterized by photoreceptor degeneration. RP1 is a major gene underlying autosomal dominant (ad) RP though prevalence numbers vary depending on the origin of the cases from 0%-10% cases. Some mutations in RP1 also lead to autosomal recessive RP. Herein we review all previously reported and several novel RP1 mutations in relation to the associated phenotype in patients from a French adRP cohort.
Background
Rod-cone dystrophies, also known as retinitis pigmentosa (RP), are a clinically and genetically heterogeneous group of progressive inherited retinal disorders, which often starts with night blindness and leads to visual field constriction and secondary macular involvement, which can eventually result in loss of central vision and complete blindness (Hartong et al. 2006) . RP occurs in 1 of 4000 births and affects more than 1 million individuals worldwide. The mode of inheritance can be x-linked (xl), autosomal dominant (ad) or autosomal recessive (ar). In addition, many patients represent isolated cases, due to the absence of family history of RP. To date, mutations in 23 different genes are associated with autosomal dominant RP (adRP) (http://www.sph.uth.tmc.edu/Retnet/) and the majority of prevalence studies reveals rhodopsin (RHO: MIM#180380) being the most frequently mutated gene in adRP (Sullivan et al. 2006; Audo et al. 2010b ). In addition, PRPF31(MIM#606419), PRPH2 (MIM#179605) and RP1 (MIM#603937) were proposed to represent major genes underlying this form of RP (Sullivan et al. 2006; Audo et al. 2010a ). In some rare cases RP1 mutations were also found in patients with arRP and unilateral RP (Khaliq et al. 2005; Riazuddin et al. 2005; Singh et al. 2009; Chen et al. 2010; Mukhopadhyay et al. 2011) . RP1 is located on chromosome 8q12.1, encompasses 4 exons of which 3 are coding. This work aims to review known mutations and to document novel mutations and genotype-phenotype correlations on a French cohort consisting of 114 cases.
Mutations in the RP1 gene
So far 39 disease causing mutations in RP1 have been identified of which most were found in the last exon, leading to a premature stop codon and are predicted to form a truncated protein (Table 1 ). The p.Arg677X has been described as the most commonly reported mutation (Bowne et al. 1999; Guillonneau et al. 1999; Pierce et al. 1999; Sullivan et al. 1999; Jacobson et al. 2000; Payne et al. 2000; Baum et al. 2001; Berson et al. 2001; Sohocki et al. 2001; Xiaoli et al. 2002; Schwartz et al. 2003; Ziviello et al. 2005; Chiang et al. 2006; Gamundi et al. 2006; Roberts et al. 2006; Sullivan et al. 2006) ..
Detailed phenotype-genotype correlations of patients with this mutation revealed incomplete penetrance and high variability of the disease expression in adRP suggesting modifiers to be involved (Jacobson et al. 2000) . Similarly, incomplete penetrance was also noted for other mutations (Table 1) . Mutation analysis in our cohort (85 of 114 adRP index patients screened for RP1) added two different deletions and two different nonsense mutations identified in 6 families to the previously described mutations, however none of the patients revealed the recurrent p.Arg677X mutation (Table 1, Supp.   Table S1 ).With our findings, to date 43 RP1 mutations are known to cause adRP. The prevalence of RP1 mutations with 5,3% in our cohort is similar to studies from UK and USA, although the prevalence of RP1 mutations varied from 0%-10% from different adRP cohorts (Bowne et al. 1999; Pierce et al. 1999; Payne et al. 2000; Baum et al. 2001; Berson et al. 2001; Sohocki et al. 2001; Kawamura et al. 2004; Ziviello et al. 2005; Gamundi et al. 2006; Roberts et al. 2006; Sullivan et al. 2006; Zhang et al. 2010) Different pathogenic mechanisms of RP1 truncating mutations have been proposed due to in vitro and in vivo studies leading to ar or adRP. Chen and co-workers proposed four classes of RP1 mutations depending on their site and underlying pathogenicity . Class 1 mutations are rare, thought to be nonsense-mediated decay (NMD)-sensitive and locate in exons 2-3 (amino acids 1-236). Haploinsufficiency is not believed to be the disease causing mechanism since heterozygous carriers of those mutations are not affected. Thus it is more likely that the mutation creates a null allele due to NMD. The RP1 protein made by the unaffected copy of the allele is completely functional and only if both alleles are affected, the patient will suffer from RP. Examples are p.Ser2ArgfsX16 ) and p.Pro229GlnfsX35 (Pierce et al. 2010) (Table 1) .
Class II mutations occur frequently and are reported to be NMD-insensitive truncations, which are located approximately between amino acids 500 and 1053 in exon 4. The mutant proteins are expected to impose distinct dominant negative effect on photoreceptors, resulting in cell death and adRP (Table 1) . Similarly, the deletions and nonsense mutations identified in the French adRP cohort studied herein could also be classified as class II mutations. Two of them (p.Lys657AsnfsX7 and p.Ile725TyrfsX13) may represent re-current mutations in French adRP patients due to the appearance in two independent families (Table 1, Supp. Figure S1 , Supp. Table S1 ). To our knowledge only one recessive truncating mutation lies in this region and leads to arRP (p.Asn949LysfsX32) ( Table 1) . Class III truncating mutations are thought to affect amino acids 264 to 499 and 1054 to 1751, which lead to loss-of-function in patients with arRP. Examples are p.Pro1648SerX13 or p.Asn1751IlefsX4 (Riazuddin et al. 2005) (Table 1) . Class IV truncating mutations are NMD-insensitive and thought to be located after amino acid 1816. The resulting truncated proteins are expected to be functional and thus not disease causing . A few missense mutations reported lead to ar or adRP (Table 1) (Khaliq et al. 2005; Chiang et al. 2006; Zhang et al. 2010) . However for most of the missense mutations the pathogenic character remains to be elucidated or was considered to be benign (Supp . Tables S2 and S3 ).
Similarly, we identified a missense mutation (c.4193C>G, p.Ser1398Cys, Supp. Figure   S1 , F745,) of which co-segregation analysis can not clearly predict if this variant lead to adRP (Supp. Table S4 ). Furthermore other variants in RP1 have been identified, which are presumably due to predictions or co-segregation analysis not pathogenic (Supp. Table   S5 ). All mutations identified by our extensive literature review and described herein, will be submitted to the existing Locus Specific Databses (LSDB) on RP1, which before the submission of our review cites only 4 pathogenic mutations.
Genotype-Phenotype correlation
Variable penetrance of the disease was observed in our and other cohorts. Most patients with RP1 mutations show classical signs of RP with relatively preserved central vision and visual field. The detailed description about the phenotypic characteristics of the 7 index patients (3 females and 4 males) carrying different RP1 mutations of the French adRP cohort can be used as key insights about RP1 associated genotype-phenotype relationships (Table 2 and 3 with an illustration of retinal changes presented in figure 1 ).
In brief, mean age of patients of the patients herein is 54.4. Except for one patient, CIC01234 (carries the missense mutation of uncertain pathogenicity) examined at an asymptomatic young age during a family investigation, the majority of subjects were diagnosed in their twenties with an average age at time of diagnosis of about 23 years. This is older than reported in adRP associated with RHO and PRPF31 mutations (Audo et al. 2010a; Audo et al. 2010b ) and in accordance with previous reports for patients with RP1 mutations (Berson et al. 2001) . Family history for two families (F556 and F745) suggested incomplete penetrance and three patients reported variable age of onset in the family with diagnosis made as late as 55 years. This is in keeping with variable penetrance and expressivity associated with RP1 mutations (Jacobson et al. 2000; Berson et al. 2001) . None of the families in this study mentioned unilateral involvement so far (Mukhopadhyay et al. 2011 ). Symptoms at presentation were dominated by night vision disturbances. Visual acuity ranges from 20/25 to 20/800. All patients had some lens opacities or had undergone cataract surgery. In most cases, fundus changes were typical of RP with narrowed retinal vessels, pale discs and pigmentary changes in the periphery.
All but one had some degree of atrophy with loss of autofluorescence in the perifoveal region and one patient also had cystoid macular oedema in one eye. Color vision abnormalities were correlated with worse visual acuities. All patients had severe constricted visual fields and generalized retinal dysfunction with four out of seven with some preservation of central macular function. Therefore, although phenotypic variability was suggested in certain families in this study, the index patients had a fairly homogeneous degree of severity within their retinal involvement.
Biological Relevance
RP1 consists of 2156 amino acids with a molecular weight of 240 kD, which is expressed specifically in photoreceptors in the retina (Bowne et al. 1999; Guillonneau et al. 1999; Pierce et al. 1999) . The N-terminal 28-228 amino acids of RP1 contains a tandem repeat domain (Kim et al. 2003) , which is known to interact with microtubules and was initially detected in the protein doublecortin (DCX). DCX is involved in directing neuronal migration during development of the central nervous system and mutations in this gene in patients lead to x-linked lissencephaly and double cortex syndrome (des Portes et al.
1998
; Gleeson et al. 1998; Francis et al. 1999) . Immunofluorescence analyses detected the human and mouse RP1 protein in the connecting cilium and microtubule-based axoneme of rod and cone photoreceptors. In addition, the amino acid sequences between codons p.486 and p.635 shares homology with the Drosophila melangonaster protein BIF, which is essential for normal photoreceptor morphogenesis (Pierce et al. 1999 ). Due to the specific localization of RP1 and the existence of the typical DCX and BIF domain, it was suggested that RP1 might participate in transport of proteins between the inner and outer segments of photoreceptors or in maintenance of the ciliary structure . Different mouse lines lacking Rp1 have been created to better understand the function and pathogenic mechanism of RP1 protein and mutations: One deletes the conserved N-terminal Dcx domain (Gao et al. 2002) and produces an abnormal Rp1 product that is lacking exon 2 and 3, while the other mimics the frequently identified mutation in RP patients: p.Arg677X, which contains the N-terminal Dcx domain and produces the shorter Rp1 protein (Liu et al. 2003) . Both homozygous models experience rapid retinal degeneration and show outer segment dysplasia and misalignment, suggesting a general role of RP1 in outer segment organization. Initially, only heterozygous mice lacking the Dcx domain and expressing about 50% of normal Rp1 protein revealed some retinal dysfunction despite normal-appearing retinal morphology (Gao et al. 2002) , while heterozygous mice mimicking the human mutation p.Arg677X did not show any phenotype (Liu et al. 2003) . However, recently it was shown that the severity of the retinal degeneration is dependent on the genetic background and only heterozygous mice for the A.129S(B6) background indeed developed RP suggesting that specific modifiers present in one or the other mouse strain are responsible for the severity of the phenotype in some heterozygous mouse lines (Liu et al. 2009 ). Furthermore the photoreceptor degeneration of a knock-in mouse line carrying the p.Gln662X mutation, analogous to the human p.Arg677X mutation, could be delayed or prevented by adding wild-type Rp1 protein (Pierce et al. 2010 ). Another mouse model, which was chemically induced (N-ethyl-N-nitrosourea = ENU) carries a p.Arg533X mutation and again only homozygous mice were affected by photoreceptor degeneration (Won et al. 2011) . Since the retinal phenotype in knock-in mice carrying mutations in this region could be delayed or prevented by adding the wild-type gene, the underlying pathogenic mechanism was suggested to be dominant-negative and not gain-of-function.
Clinical and Diagnostic Relevance
In the study presented here we review all reported disease causing RP1 mutations including 4 novel truncating mutations and 1 novel nucleotide change of uncertain pathogenicity in 7 cases with a homogenous RP phenotype (Table 1, 2 and 3, Supp.   Tables S1 and S2 ). Our study confirms that for adRP European cohorts, RP1 represents a major gene defect. We propose that most of the RP1 mutations leading to adRP represent truncation mutations and are located in a hot spot region (~nucleotides c.1490-c.3216).
Therefore, to perform a time and cost-efficient mutations screening for adRP patients this region could be preferentially targeted. These truncating mutations can be classified as Class II mutations, which lead to a dominant negative effect of RP1 resulting in photoreceptor cell degeneration. In addition, incomplete penetrance was observed for some of the mutations in this class (Dietrich et al. 2002; Roberts et al. 2006) (Table 1 ).
The exact mechanism of this incomplete penetrance is not known. Another form of adRP associated with mutation in splicing factors is also associated with incomplete penetrance (Evans et al. 1995; Al-Maghtheh et al. 1996; McGee et al. 1997; Vaclavik et al. 2010) . In this case, haploinsufficiency is the admitted disease mechanism and an allelic imbalance with overexpression of the wild-type allele, compensating for the non-functional allele in asymptomatic carriers has been advocated (Vithana et al. 2003; Rivolta et al. 2006 ). In case of incomplete penetrance associated with RP1 mutation, such mechanisms with the influence of the trans allele has been suggested in asymptomatic female carriers by Daiger and colleagues but warrants further study (Daiger et al. 2006) . Influence of mouse strains of Rp1 mutation upon severity in retinal degeneration advocate for modifying factors (Liu et al. 2009) . A better understanding of the mechanisms underlying phenotypic variability should facilitate developing novel therapeutic approaches.
Clinically and genetically well-characterized patients such as those included here are critical in this regard.
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FIGURE LEGENDS
Figure 1: Fundus autofluorescence and optical coherence appearance in 2 patients from this French cohort with RP1 truncating mutations.
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Methods
Clinical assessment
Patients with a provisional diagnosis of autosomal dominant rod-cone dystrophy, (adRP) were ascertained in the Clinical Investigating Centre of Quinze-Vingts Hospital. Informed consent was obtained from each patient and normal controls after explanation of the study and its potential outcome. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committee. Each patient underwent full ophthalmic examination with clinical assessment as described earlier (Audo et al., 2010, RHO mutations). For additional family members who could not come to our centre for examination, ophthalmic records were obtained from local ophthalmologists.
Mutation detection
Total genomic DNA was extracted from peripheral blood leucocytes according to manufacturer recommendation (Puregen Kit, Qiagen, Courtaboeuf, France). Subsequently, direct genomic sequencing of RP1 (Accession Number: NM_006269.1) was performed. All 4 exons of which exons 2-4 are coding, and flanking intronic regions of RP1 were PCR amplified in 20 fragments (RP1 RefSeq NM_006269.1) using a polymerase (HotFire, Solis Biodyne, Estonia) in the presence of 1.5 mM MgCl 2 and at an annealing temperature of 58°C (Primers can be obtained by request). The PCR products were enzymatically purified (ExoSAP-IT, USB Corporation, Cleveland, Ohio, USA purchased from GE Healthcare, Orsay, France) and sequenced with a commercially available sequencing mix (BigDyeTerm v1.1 CycleSeq kit, Applied Biosystems, Courtaboeuf, France). The sequenced products were purified on a presoaked Sephadex G-50 (GE Healthcare) 96-well multiscreen filter plate (Millipore, Molsheim, France), the purified product analyzed on an automated 48-capillary sequencer (ABI 3730 Genetic analyzer, Applied Biosystems) and the results interpreted by applying a software (SeqScape, Applied Biosystems Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence NM_006269.1, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
